HIVEP3 inhibits fate decision of CD8+ invariant NKT cells after positive selection
Journal of Leukocyte Biology · 2023
DOI: 10.1093/jleuko/qiad082 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Leukocyte Biology, 2023. Verfasst von Qielan Wu und 21 weiteren Autor:innen. Beteiligte Einrichtung: Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of…. Hauptthemen laut MEDLINE: Natural Killer T-Cells, CD8-Positive T-Lymphocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, University Synergy Innovation Program of Anhui Province.
Abstract (Originalsprache)
CD8+ invariant natural killer T (iNKT) cells are functionally different from other iNKT cells and are enriched in human but not in mouse. To date, their developmental pathway and molecular basis for fate decision remain unclear. Here, we report enrichment of CD8+ iNKT cells in neonatal mice due to their more rapid maturation kinetics than CD8− iNKT cells. Along developmental trajectories, CD8+ and CD8− iNKT cells separate at stage 0, following stage 0 double-positive iNKT cells, and differ in HIVEP3 expression. HIVEP3 is lowly expressed in stage 0 CD8+ iNKT cells and negatively controls their development, whereas it is highly expressed in stage 0 CD8− iNKT cells and positively controls their development. Despite no effect on IFN-γ, HIVEP3 inhibits granzyme B but promotes interleukin-4 production in CD8+ iNKT cells. Together, we reveal that, as a negative regulator for CD8+ iNKT fate decision, low expression of HIVEP3 in stage 0 CD8+ iNKT cells favors their development and T helper 1–biased cytokine responses as well as high cytotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, No. 443 Huangshan Street, Shushan District, Hefei 230027, Chin…
- Biomedical Sciences and Health Laboratory of Anhui Province, Division of Life Sciences and Medicine, University of Science and Technology of China, No. 443 Huangshan Street, Shushan District, Hefei 230027, China.
- Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, Institute of Molecular Medicine, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, School of Medicine, S…
- Institute of Health and Medicine, Hefei Comprehensive National Science Center, 4090 Susong Road, Shushan District, Hefei 230601, China.
- National Synchrotron Radiation Laboratory, University of Science and Technology of China, No. 443 Huangshan Street, Shushan District, Hefei 230027, China.
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- University Synergy Innovation Program of Anhui Province
- Natural Science Foundation of Hefei
Zitieren
APA
Wu, Q., Bai, S., Su, M., Zhang, Y., Chen, X., Yue, T., Xu, L., Wang, L., Xie, D., Li, S., Li, X., Fu, S., Wang, L., Tian, C., Pan, J., Huang, Y., Cai, Y., Wang, Y., Hu, F., …, & Bai, L. (2023). HIVEP3 inhibits fate decision of CD8+ invariant NKT cells after positive selection. Journal of Leukocyte Biology. https://doi.org/10.1093/jleuko/qiad082
Vancouver
Wu Q, Bai S, Su M, Zhang Y, Chen X, Yue T, et al. HIVEP3 inhibits fate decision of CD8+ invariant NKT cells after positive selection. Journal of Leukocyte Biology. 2023. doi:10.1093/jleuko/qiad082
BibTeX
@article{Wu2023,
author = {Wu, Qielan and Bai, Shiyu and Su, Miya and Zhang, Yuwei and Chen, Xuran and Yue, Ting and Xu, Linfeng and Wang, Lu and Xie, Di and Li, Shuhang and Li, Xiang and Fu, Sicheng and Wang, Lili and Tian, Chenxi and Pan, Jun and Huang, Yuanyuan and Cai, Yuting and Wang, Yu and Hu, Fang and Li, Fengyin and Zhang, Huimin and Bai, Li},
title = {HIVEP3 inhibits fate decision of CD8+ invariant NKT cells after positive selection},
journal = {Journal of Leukocyte Biology},
year = {2023},
doi = {10.1093/jleuko/qiad082}
}
EUVIMED